Vera Therapeutics to Participate at Upcoming Investor Conferences
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company developing treatments for serious immunological diseases, has announced its management team's participation in two upcoming investor conferences. The team will participate in:
1. The Guggenheim Securities Healthcare Innovation Conference on November 13, 2024, at 9:30am EST in Boston, MA, featuring a fireside chat and one-on-one meetings.
2. The 7th Annual Evercore ISI HealthCONx Conference on December 5, 2024, at 7:55am EST in Coral Gables, FL, also including a fireside chat and one-on-one meetings.
Webcasts will be available for both events, with replays accessible for 90 days through Vera's website.
Vera Therapeutics (Nasdaq: VERA), una società biotecnologica in fase clinica avanzata che sviluppa trattamenti per gravi malattie immunologiche, ha annunciato la partecipazione del suo team di gestione a due prossime conferenze per investitori. Il team parteciperà a:
1. La Guggenheim Securities Healthcare Innovation Conference il 13 novembre 2024, alle 9:30 EST a Boston, MA, che prevede un incontro 'fireside chat' e incontri individuali.
2. La 7a Conferenza Annuale Evercore ISI HealthCONx il 5 dicembre 2024, alle 7:55 EST a Coral Gables, FL, che includerà anch'essa un incontro 'fireside chat' e incontri one-on-one.
Saranno disponibili webcast per entrambi gli eventi, con le riprese accessibili per 90 giorni tramite il sito web di Vera.
Vera Therapeutics (Nasdaq: VERA), una empresa de biotecnología en etapa clínica avanzada que desarrolla tratamientos para enfermedades inmunológicas graves, ha anunciado la participación de su equipo directivo en dos próximas conferencias para inversores. El equipo participará en:
1. La Guggenheim Securities Healthcare Innovation Conference el 13 de noviembre de 2024, a las 9:30 EST en Boston, MA, que contará con una charla 'fireside chat' y reuniones individuales.
2. La 7ª Conferencia Anual Evercore ISI HealthCONx el 5 de diciembre de 2024, a las 7:55 EST en Coral Gables, FL, que también incluirá una charla 'fireside chat' y reuniones uno a uno.
Se ofrecerán transmisiones web para ambos eventos, con repeticiones accesibles durante 90 días a través del sitio web de Vera.
베라 테라퓨틱스 (Nasdaq: VERA), 심각한 면역 질환을 위한 치료제를 개발하는 후기 임상 단계의 생명공학 회사는 경영진 팀이 두 개의 투자자 회의에 참석할 것임을 발표했습니다. 팀은 다음 회의에 참석합니다:
1. 구겐하임 증권 헬스케어 혁신 회의 2024년 11월 13일 오전 9시 30분 EST, 보스턴, MA에서 진행되며, 대화 형식의 토론 및 일대일 회의가 포함됩니다.
2. 제7회 에버코어 ISI 헬스CONx 회의 2024년 12월 5일 오전 7시 55분 EST, 코랄 게이블스, FL에서 진행되며, 역시 대화 형식의 토론 및 일대일 회의가 포함됩니다.
양쪽 행사 모두 웹캐스트가 제공되며, 재방송은 베라의 웹사이트를 통해 90일간 접근 가능합니다.
Vera Therapeutics (Nasdaq: VERA), une société biopharmaceutique en phase clinique avancée développant des traitements pour des maladies immunologiques graves, a annoncé la participation de son équipe de direction à deux conférences d'investisseurs à venir. L'équipe participera à :
1. La Guggenheim Securities Healthcare Innovation Conference le 13 novembre 2024 à 9h30 EST à Boston, MA, comprenant une discussion 'fireside chat' et des réunions en tête-à-tête.
2. La 7ème Conférence Annuelle Evercore ISI HealthCONx le 5 décembre 2024 à 7h55 EST à Coral Gables, FL, qui incluera également une discussion 'fireside chat' et des réunions individuelles.
Des webcasts seront disponibles pour les deux événements, avec des rediffusions accessibles pendant 90 jours via le site Web de Vera.
Vera Therapeutics (Nasdaq: VERA), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das Behandlungen für schwere immunologische Erkrankungen entwickelt, hat die Teilnahme seines Managementteams an zwei kommenden Investorenkonferenzen angekündigt. Das Team wird an folgenden Veranstaltungen teilnehmen:
1. Der Guggenheim Securities Healthcare Innovation Conference am 13. November 2024 um 9:30 Uhr EST in Boston, MA, die eine 'fireside chat'-Diskussion und Einzelgespräche umfasst.
2. Der 7. Jahrestagung Evercore ISI HealthCONx am 5. Dezember 2024 um 7:55 Uhr EST in Coral Gables, FL, die ebenfalls eine 'fireside chat'-Besprechung und Einzelgespräche beinhaltet.
Für beide Veranstaltungen werden Webcasts verfügbar sein, und Aufzeichnungen sind für 90 Tage über die Website von Vera zugänglich.
- None.
- None.
BRISBANE, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
Investor Conference Details:
- Guggenheim Securities Healthcare Innovation Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/guggen/vera/1942294
Date: Wednesday, November 13, 2024
Time: 9:30am EST
Location: Boston, MA
- 7th Annual Evercore ISI HealthCONx Conference
Format: Fireside Chat and 1x1s
Webcast: https://wsw.com/webcast/evercore44/vera/2364138
Date: Thursday, December 5, 2024
Time: 7:55am EST
Location: Coral Gables, FL
A replay of the webcast will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When is Vera Therapeutics (VERA) presenting at the Guggenheim Securities Healthcare Conference in 2024?
What type of events will VERA participate in at the Evercore ISI HealthCONx Conference 2024?
How long will the webcasts from VERA's investor conferences be available for replay?
